Chugai partners on novel cancer drugs using bifidobacterium

22 October 2018

Chugai Pharmaceutical (TYO: 4519) has concluded a collaborative research agreement with privately held fellow Japanese biopharmaceutical company Anaeropharma Science concerning the creation of novel oncology drugs utilizing characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, "in situ Delivery and Production System" (i-DPS).

Under the agreement, Anaeropharma and Chugai, which is majority owned by Swiss pharma giant Roche (ROG: SIX), will conduct joint research regarding specific oncology substances by use of Anaeropharma's i-DPS technology and Chugai's technology.

The scope of the agreement is limited to the specific substances predetermined by both companies, and the i-DPS technology will be applied only to those substances. No financial terms of the collaboration have been disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK